This work also reported an improved anti-tumor immune response when combining OLT1177 with anti-PD-1 antibody therapy in the B16/F10 melanoma model and inferred that this was due to inhibition of melanoma-dependent IL-1β secretion. Here, IL1B is linked to neoplasm.